Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose mass balance and metabolite profiling study of 14C-labeled izicopan in healthy male participants
NL-OMON61099Phase 1Active, not recruiting
- Sponsor
- InflaRx
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izicopan, sponsored by InflaRx. Primary endpoint: Primary endpoint(s). Started May 2026; status: active, not recruiting.
02
Drugs
izicopan
Beyond the preview
Go deeper on NL-OMON61099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61099.